Anixa biosciences initiates dosing in third cohort in its ovarian cancer car-t clinical trial

Third cohort dose is one million car positive cells; ten times higher than the first cohort dose san jose, calif. , nov. 18, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the third cohort in the ongoing phase 1 clinical trial of its novel chimeric antigen receptor-t cell (car-t) therapy for recurrent ovarian cancer.
CAR Ratings Summary
CAR Quant Ranking